PHARMACY

Teva introduces antibiotic for oral suspension

BY Alaric DeArment

NORTH WALES, Pa. Generic drug maker Teva Pharmaceuticals has introduced azithromycin for oral suspension USP, Teva announced Monday.

The antibiotic is AB rated and bioequivalent to Pfizer’s Zithromax for oral suspension and available in 100 mg per 5 mL strength in 15 mL bottles and 200 mg per 5 mL strengths, in 15 mL, 22.5 mL and 30 mL bottles.

“Generic pharmaceuticals are playing an increasingly important role in healthcare cost containment,” Teva vice president of sales and marketing John Denman said. “Teva Pharmaceuticals continues to lead the way with timely new product launches.”

Zithromax, also sold as Zmax, had sales of $438 million in 2007, according to Pfizer financial data.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Study questions Lipitor’s efficacy for women

BY Alaric DeArment

NEW YORK A study published in the Journal of Empirical Legal Studies has shown that Pfizer’s blockbuster drug Lipitor does little to reduce the risk of cardiovascular problems in women.

The study was based on analysis of previous studies on drugs’ effects on cardiovascular health in men and women. Studies had shown that the reduction in heart attack risk was statistically significant in men who used Lipitor (atorvastatin calcium), but not in women.

“Our findings indicate that each year, reasonably health women spend billions of dollars on drugs in the hope of preventing heart attacks but that scientific evidence supporting their hope does not exist.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Study shows long-term use of Avonex improves quality of life

BY Alaric DeArment

MONTREAL Data from a study has shown long-term benefits among patients using Avonex to treat relapsing multiple sclerosis, drug maker Biogen Idec announced Thursday.

The study—called Assessment of Drug Utilization, Early Treatment and Clinical Outcomes, or ASSURANCE—represented a long-term follow-up of patients who participated in the Multiple Sclerosis Collaborative Research Group, the original phase III pivotal trial from which Avonex (interferon beta-1a IM) was approved.

“As a physician, my goal in treating my MS patients is to delay disability progression and help them maintain their normal lifestyle for as long as possible,” said Robert Bermel of the Mellen Center for Multiple Sclerosis Treatment and Research at the Cleveland Clinic. “This follow-up study identifies a group of patients who achieved benefits from long-term treatment and underscores the importance of starting on and continuing an effective therapy for MS.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?